Data from PALOMA-2 reinforced ER status as a significant marker for therapeutic benefit with observations supporting that this breast cancer subtype is dependent on the CDK4/6:cyclin D:retinoblastoma pathway [30]. This evidence concerns the gene CDK4 and breast carcinoma.